A. Passioukov

827 total citations
15 papers, 198 citations indexed

About

A. Passioukov is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, A. Passioukov has authored 15 papers receiving a total of 198 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in A. Passioukov's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Diagnosis and Treatment (3 papers) and HER2/EGFR in Cancer Research (3 papers). A. Passioukov is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Diagnosis and Treatment (3 papers) and HER2/EGFR in Cancer Research (3 papers). A. Passioukov collaborates with scholars based in Switzerland, France and United Kingdom. A. Passioukov's co-authors include Paul Baas, John J. Welch, Baktiar Hasan, Laurent Greillier, Thomas J. Lobl, André Trouet, Vincent Dubois, R. Baurain, Kim Van derpoorten and Cecilia Oliyai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

A. Passioukov

15 papers receiving 194 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Passioukov Switzerland 7 90 80 57 43 36 15 198
Р. В. Орлова Russia 7 107 1.2× 65 0.8× 67 1.2× 42 1.0× 12 0.3× 59 236
Lintong Yao China 9 53 0.6× 70 0.9× 137 2.4× 40 0.9× 63 1.8× 21 259
Yoshihiro Hattori Japan 9 215 2.4× 188 2.4× 54 0.9× 18 0.4× 11 0.3× 28 298
Guzel Mukhametshina Russia 7 143 1.6× 91 1.1× 26 0.5× 49 1.1× 46 1.3× 15 190
Luigi Della Gravara Italy 8 117 1.3× 102 1.3× 54 0.9× 25 0.6× 9 0.3× 21 192
Lanqing Cao China 10 66 0.7× 60 0.8× 121 2.1× 15 0.3× 23 0.6× 21 281
Karie Runcie United States 6 114 1.3× 66 0.8× 101 1.8× 69 1.6× 62 1.7× 27 227
Veena S. John United States 7 142 1.6× 24 0.3× 102 1.8× 58 1.3× 88 2.4× 26 268
Helen L. Lowe United Kingdom 10 195 2.2× 32 0.4× 179 3.1× 17 0.4× 41 1.1× 16 380
Neelesh Sharma United States 7 82 0.9× 74 0.9× 86 1.5× 8 0.2× 13 0.4× 16 196

Countries citing papers authored by A. Passioukov

Since Specialization
Citations

This map shows the geographic impact of A. Passioukov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Passioukov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Passioukov more than expected).

Fields of papers citing papers by A. Passioukov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Passioukov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Passioukov. The network helps show where A. Passioukov may publish in the future.

Co-authorship network of co-authors of A. Passioukov

This figure shows the co-authorship network connecting the top 25 collaborators of A. Passioukov. A scholar is included among the top collaborators of A. Passioukov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Passioukov. A. Passioukov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Caudell, David L., Gregory O. Dugan, Christine M. Schubert, et al.. (2024). Systemic immune response to a CD40 agonist antibody in nonhuman primates. Journal of Leukocyte Biology. 115(6). 1084–1093. 2 indexed citations
2.
Cruzalegui, Francisco, Noureddine Loukili, Olivier Delfour, et al.. (2020). Abstract 3372: VISTA interaction with PSGL1, a likely VISTA receptor in tumors, is effectively disrupted by K0401-020 anti-VISTA antibody. Cancer Research. 80(16_Supplement). 3372–3372. 6 indexed citations
3.
Gomez‐Roca, Carlos, Elena Garralda, Francisco Cruzalegui, et al.. (2018). First-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population. Annals of Oncology. 29. viii145–viii146. 1 indexed citations
4.
5.
Oppenheim, David, Roberto Spreafico, Annie Etuk, et al.. (2014). Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. British Journal of Cancer. 110(5). 1221–1227. 22 indexed citations
6.
Delord, Jean‐Pierre, Josep Tabernero, Rocio García‐Carbonero, et al.. (2013). Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. European Journal of Cancer. 50(3). 496–505. 22 indexed citations
7.
8.
Felip, Enriqueta, Malcolm Ranson, S. Cedrés, et al.. (2010). Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7540–7540. 1 indexed citations
9.
Greillier, Laurent, Paul Baas, John J. Welch, Baktiar Hasan, & A. Passioukov. (2008). Biomarkers for Malignant Pleural Mesothelioma. Molecular Diagnosis & Therapy. 12(6). 375–390. 43 indexed citations
10.
11.
12.
13.
14.
Trouet, André, A. Passioukov, Kim Van derpoorten, et al.. (2001). Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.. PubMed. 61(7). 2843–6. 55 indexed citations
15.
Trouet, A., A. Passioukov, R. Baurain, et al.. (2000). CPI-0004Na An extracellularly tumor-activated prodrug of doxorubicin. 41. 522. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Р. В. Орлова Breakdown of academic impact, for papers by Lintong Yao Breakdown of academic impact, for papers by Yoshihiro Hattori Breakdown of academic impact, for papers by Guzel Mukhametshina Breakdown of academic impact, for papers by Luigi Della Gravara Breakdown of academic impact, for papers by Lanqing Cao Breakdown of academic impact, for papers by Karie Runcie Breakdown of academic impact, for papers by Veena S. John Breakdown of academic impact, for papers by Helen L. Lowe Breakdown of academic impact, for papers by Neelesh Sharma
Rankless by CCL
2026